Recent News

• 02.05.2026 - Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
• 02.04.2026 - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 01.12.2026 - Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
• 01.07.2026 - Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
• 01.05.2026 - Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
• 12.12.2025 - Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
• 12.08.2025 - Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
• 12.03.2025 - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 11.05.2025 - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 11.03.2025 - Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 01.30.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.12.2026 - EX-99.1 EX-99.1
• 01.12.2026 - 8-K Current report
• 12.19.2025 - 8-K Current report
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2025 - 8-K Current report
• 11.03.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2025 - EX-99.1 EX-99.1